Abstract
Over the past two decades, there has been a considerable improvement in survival of patients with cancer. Prevention, screening and early detection, and treatment, have been credited with the reduction in mortality. The last two years have seen an overwhelming amount of publications on the use of immune checkpoint inhibitors for the management of various cancers. The claims are astounding. Difficult-to-treat cancers respond to the treatment, and patients live longer with good quality of life. Given the excitement, the all-important question to ask is whether ‘immunotherapy’ will prove to be another incremental gain, frequently observed in cancer practice over the past half-century, or is it going to be one of the few quantum leaps, rarely observed in clinical practice?
Publication details
- DOI
- 10.5001/omj.2017.01
- Journal
- Oman Medical Journal
- Publisher
- Oman Medical Specialty Board
- Open access
- Gold open access
Cite this article
APA 7
Burney, I. A. (2017). Immunotherapy in Cancer: Incremental Gain or a Quantum Leap? Oman Medical Journal. https://doi.org/10.5001/omj.2017.01
MLA 9
Burney, Ikram A. "Immunotherapy in Cancer: Incremental Gain or a Quantum Leap?" Oman Medical Journal, 2017. https://doi.org/10.5001/omj.2017.01.
Chicago (author–date)
Burney, Ikram A. 2017. "Immunotherapy in Cancer: Incremental Gain or a Quantum Leap?" Oman Medical Journal. https://doi.org/10.5001/omj.2017.01.
Harvard
Burney, I. A. (2017) 'Immunotherapy in Cancer: Incremental Gain or a Quantum Leap?', Oman Medical Journal. doi:10.5001/omj.2017.01.
Vancouver
Burney IA. Immunotherapy in Cancer: Incremental Gain or a Quantum Leap? Oman Medical Journal. 2017. doi:10.5001/omj.2017.01
IEEE
I. A. Burney, "Immunotherapy in Cancer: Incremental Gain or a Quantum Leap?," Oman Medical Journal, 2017, doi: 10.5001/omj.2017.01.